FIELD: chemistry.
SUBSTANCE: present invention refers to immunology. Disclosed is an anti-alpha-enolase (ENO1) antibody, as well as its scFv and Fab fragment. Also described is a pharmaceutical composition for treating a malignant neoplasm; as well as a method for diagnosing a malignant neoplasm and a method for inhibiting the invasion of a malignant neoplasm. Antibody of the invention is capable of binding to peptides comprising the amino acid sequence FDQDDWGAWQKFTA and / or KRIAKAVNEKS of the human protein ENO1 and has a suitable binding activity (binding affinity is about 10-10 mol/l).
EFFECT: present invention can find further application in the therapy and diagnosis of diseases associated with ENO1.
8 cl, 17 dwg, 3 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SPECIFIC ANTIBODIES TO ALPHA-ENOLASE AND METHOD OF USING IN IMMUNE DISEASES | 2014 |
|
RU2707812C1 |
| HUMANIZED ANTIBODIES SPECIFIC TO ALPHA-ENOLASE AND METHODS FOR USE IN ANTITUMOR THERAPY | 2014 |
|
RU2761662C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| CD3-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND THEIR APPLICATIONS | 2020 |
|
RU2808138C1 |
| CANINISED MURINE ANTIBODIES TO HUMAN PD-1 | 2014 |
|
RU2676158C1 |
| IL2 ANTIBODIES | 2006 |
|
RU2425054C2 |
| ANTIBODIES TO HER3 AND APPLICATION THEREOF | 2010 |
|
RU2560583C2 |
| ANTIGEN BINDING PROTEIN AND USE THEREOF AS ADDRESSING PRODUCT FOR TREATMENT OF CANCER | 2012 |
|
RU2659094C2 |
| CSF-1R ANTIBODY | 2009 |
|
RU2547586C2 |
